Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Inactivated Rift Valley Fever Vaccine (TSI-GSD 200)
NCT00869713Phase 2Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Sep 2009
- Primary completion
- Feb 2019
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rift valley fever vaccine (inactivated) in Rift Valley fever (RVF), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: PRNT80 ≥ 1:40 after primary series, PRNT80 ≥ 1:40 after 6-month mandatory booster dose and 4 more. Started Sep 2009; status: completed.
02
Drugs
rift valley fever vaccine (inactivated)
03
Conditions
Rift Valley fever (RVF)
Beyond the preview
Go deeper on NCT00869713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00869713.